Fuji-Keizai U.S.A. published a market research report on the biochip business in August 2006. Since that early report, more than 18 months have passed and the biochip business has continued to change at a fast pace.
We study the biochip business extensively, analyzing where marketplace change is most intense and reporting the trends, new fields of use, and the global market prospects for companies seeking to gain or reclaim market share or strengthen their market positions.
Our research objectives within the biochip segment are DNA/RNA chips, devices, software and services; Lab-on-Chip devices and services; Protein chips/devices; and Special-Purpose Biochips.
This report discusses new biochip products now reaching the market. DNA/ RNA products discussed include high-density tiling, copy number variation, SNPs, alternate splice variant, ChIP-Chip, CpG island, DNA methylation, microRNA, molecular diagnostic biochips and related areas such as sequencing. New lab-on-a-chip/ microfluidic biochips for Point-of-Care (POC) diagnostics, through credit card-size devices for liquid chromatography or for drug discovery optimization, will be reviewed. New commercial developments in protein biochips and related biosensors will also be examined.
The report breaks each biochip product segment into macro taxonomies, as shown in the table below. The table format serves as a very useful reference tools that brings important information to the surface and lets our reader quickly and clearly see the major trends.
(0 items)
